Precision Oncology: Molecular Genotyping and Optimal Treatment of Metastatic Nonsquamous NSCLC

Expert oncologists discuss the role of molecular genotyping in metastatic nonsquamous NSCLC in the context of of latest clinical research and consider its impact on treatment selection.

EP. 1: Advancements in Precision Oncology: Metastatic NSCLC Treatment Landscape

November 20th 2023

Explore the dynamic landscape of metastatic non-squamous non-small cell lung cancer treatment, focusing on molecular genotyping, targeted therapies, and the evolving standard of care.

EP. 2: Patient Scenario: Navigating Molecular Testing Dilemmas in Metastatic NSCLC

November 20th 2023

Experts review a patient scenario of metastatic non-squamous NSCLC and discuss complexities and challenges of initiating timely molecular testing, examining its impact on treatment decisions and patient outcomes.

EP. 3: Identifying Key Molecular Targets in Metastatic NSCLC

November 27th 2023

Shared insight into the comprehensive list of molecular targets in metastatic NSCLC, from point mutations like EGFR and KRAS to fusions such as ALK and ROS1, understanding the challenges of comprehensive testing and treatment implications.

EP. 4: Decoding Lung Cancer Mutations: Navigating Molecular Profiling in Practice

November 27th 2023

Key opinion leaders Charu Aggarwal, MD, MPH, and Melina E. Marmarelis, MD, reflect on their institution’s practices with regard to molecular profiling and its impact on treatment pathways in the setting of metastatic NSCLC.

EP. 5: Impact of Molecular Testing on Lung Cancer Survival: Real-world Insights

December 4th 2023

A comprehensive study on the association between the availability of molecular genotyping results and overall survival in advanced non-squamous, non-small cell lung cancer patients, shedding light on the importance of timely and concurrent testing.

EP. 6: Barriers in Concurrent Testing for mNSCLC: Real-world Challenges and Solutions

December 4th 2023

Experts reflect on the mixed enthusiasm for concurrent liquid and tissue testing, addressing insurance coverage concerns and the importance of shortening turnaround time, while highlighting efforts to make comprehensive testing the default in the community.

EP. 7: Metastatic NSCLC: Key Challenges in Molecular Testing and Treatment Access

December 11th 2023

Explore the complexities of limited molecular genotyping availability, the importance of comprehensive testing, and challenges in accessing target therapies, including cost considerations, in real-world clinical practice.

EP. 8: Advancements in Targeted Therapy for Metastatic NSCLC

December 11th 2023

Shared insight into the transformative impact of targeted therapies in lung cancer treatment, from adjuvant therapy breakthroughs to emerging trials, emphasizing the critical role of comprehensive molecular testing.